Zai Lab Limited (ZLAB) Launches Hong Kong Secondary Listing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
Zai Lab Launches Hong Kong Secondary Listing
September 16, 2020 7:15 AM EDTSHANGHAI and SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab or the Company) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced the launch of its Hong Kong public offering (the Hong Kong Public Offering), which forms part of the global offering (the Offering) of 10,564,050 new ordinary shares (the Offer Shares or Shares) and listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the Hong Kong Stock Exchange) under the stock code 9688.
The Companys American depositary shares (ADSs), each representing one (1)Â ordinary share of the Company,... More
